Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.
Keep Up With McLean!
Receive the latest news in your inbox each month.
July 14, 2020
Dr. Eric L. Ross and collaborators examine the cost-effectiveness of esketamine, a novel intranasally dosed antidepressant for patients with treatment-resistant depression.